Open AccessTargeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy
Author(s) -
Oluwaseun O. Akinduro,
Paola SuárezMeade,
Diogo Moniz-Garcia,
Desmond Brown,
Rachel Sarabia-Estrada,
Steven Attia,
Ziya L. Gokaslan,
Alfredo QuiñonesHinojosa
Publication year - 2021
Publication title -
targeted oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.697
H-Index - 40
eISSN - 1776-260X
pISSN - 1776-2596
DOI - 10.1007/s11523-021-00814-5
Subject(s) - medicine , chordoma , clinical trial , targeted therapy , oncology , radiation therapy , progression free survival , combination therapy , surgery , overall survival , cancer
Chordoma is a rare but devastating tumor that arises in the cranial skull base or spine. There are currently no US Food and Drug Administration-approved targeted therapies for chordoma, and little understanding of whether using more than one therapy has benefit over monotherapy.